Thyrocare's net profit jumps 82% to Rs 48 crore in Q2FY26; revenue stood at Rs 217 crore

Diagnostic major Thyrocare Technologies Ltd has reported a strong set of results for the quarter ended September 30, 2025, with revenue up 22% year-on-year and profit after tax rising 82%, supported by robust growth in its pathology segment and operational efficiency.

Advertisment

Thyrocare posted consolidated revenue of Rs 216.53 crore, up 22% YoY, driven by a 24% surge in the pathology segment. Franchise revenue grew 20%, while partnership revenue rose sharply by 35%. Normalized EBITDA grew 49% YoY to Rs 75.36 crore.

Profit after tax (PAT) climbed 82% YoY to Rs 47.90 crore, with an EBITDA margin of 33% and a gross margin of 72%. The company processed an all-time high of 53.3 million diagnostic tests in Q2FY26, a 21% increase YoY, reinforcing its leadership as India’s largest diagnostic test volume processor.

Notably, the company remains debt-free on a consolidated basis, holding over Rs 190 crore in net cash and short-term investments.

Thyrocare also announced a 2:1 bonus share issue and an interim dividend of Rs 7 per share (pre-bonus). Bonus Shares and Dividend Thyrocare’s Board of Directors approved the issuance of two bonus equity shares for every one fully paid-up equity share held, subject to statutory, regulatory, and shareholder approvals. 

Additionally, the board declared an interim dividend of Rs 7 per equity share of face value Rs 10 each, with October 24, 2025 as the record date.

In the first half of FY26, the company added four new laboratories in Vijayawada, Bhagalpur, Roorkee, and Kashmir to expand its regional presence and improve service accessibility. The company said this expansion aligns with its strategy to deepen penetration in underserved regions and strengthen its national network.

“These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India,” said Rahul Guha, MD & CEO, Thyrocare Technologies Ltd. 

“As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey,” said Alok Kumar Jagnani Group CFO.